SCHEMBL15965638

SCHEMBL15965638

Oc1ccc(O)c(/C=N/Nc2ccc3ccccc3n2)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 11/20 0.60
MAPT P10636 10/20 0.60
NPC1 O15118 9/20 0.60
SMN1; SMN2 Q16637 8/20 0.60
RAB9A P51151 8/20 0.60
HTT P42858 8/20 0.60
TP53 P04637 2/20 0.60
NFKB1 P19838 1/20 0.60
NFKB2 Q00653 1/20 0.60
RELA Q04206 1/20 0.60
ALDH1A1 P00352 5/20 0.55
HSP90AA1 P07900 2/20 0.55
CYP1A2 P05177 1/20 0.55
CYP3A4 P08684 1/20 0.55
CYP2D6 P10635 1/20 0.55
CYP2C9 P11712 1/20 0.55
ALOX15 P16050 1/20 0.55
CYP2C19 P33261 1/20 0.55
KDM4E B2RXH2 10/20 0.53
MEN1 O00255 9/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1165227 0.91 KMT2A (0.64) KMT2AMAPTNPC1SMN1; SMN2RAB9A
SCHEMBL1165226 0.91 KMT2A (0.64) KMT2AMAPTNPC1SMN1; SMN2RAB9A
SCHEMBL19535032 0.87 KMT2A (0.64) KMT2AMAPTNPC1SMN1; SMN2RAB9A
SCHEMBL19535031 0.87 KMT2A (0.64) KMT2AMAPTNPC1SMN1; SMN2RAB9A
SCHEMBL1164950 0.86 SMN1; SMN2 (0.63) KMT2AMAPTNPC1SMN1; SMN2RAB9A
SCHEMBL1164949 0.86 SMN1; SMN2 (0.63) KMT2AMAPTNPC1SMN1; SMN2RAB9A
SCHEMBL4405365 0.86 KMT2A (0.70) KMT2AMAPTNPC1SMN1; SMN2RAB9A
SCHEMBL1165602 0.84 ALDH1A1 (0.63) KMT2AMAPTNPC1SMN1; SMN2RAB9A
SCHEMBL1165599 0.84 ALDH1A1 (0.63) KMT2AMAPTNPC1SMN1; SMN2RAB9A
SCHEMBL17897810 0.80 ALDH1A1 (0.69) KMT2AMAPTNPC1SMN1; SMN2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9447059-B2 Intermediate for manufacture of polymerizable compound and process for manufacture thereof ZEON CORPORATION (JP) 2016-09-20 US disclosed
US-9447059-B2 Intermediate for manufacture of polymerizable compound and process for manufacture thereof ZEON CORPORATION (JP) 2016-09-20 US disclosed
US-20140235857-A1 INTERMEDIATE FOR MANUFACTURE OF POLYMERIZABLE COMPOUND AND PROCESS FOR MANUFACTURE THEREOF ZEON CORPORATION (JP) 2014-08-21 US disclosed
US-20140235857-A1 INTERMEDIATE FOR MANUFACTURE OF POLYMERIZABLE COMPOUND AND PROCESS FOR MANUFACTURE THEREOF ZEON CORPORATION (JP) 2014-08-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140235857-A1 INTERMEDIATE FOR MANUFACTURE OF POLYMERIZABLE COMPOUND AND PROCESS FOR MANUFACTURE THEREOF COASY, CYBA, CYP1B1 KMT2A 368/4885MAPT 2005/4885NPC1 3093/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.